Dr. Martens PLC CFO Appointment (2912T)
14 11월 2023 - 4:00PM
UK Regulatory
TIDMDOCS
RNS Number : 2912T
Dr. Martens PLC
14 November 2023
14 November 2023
Dr. Martens plc
CFO appointment
Dr. Martens plc ('the Company') announces that Giles Wilson has
been appointed to the role of Chief Financial Officer (CFO). Giles
will join Dr. Martens and take up his role in 2024, with the date
to be confirmed and announced in due course.
Giles is an experienced CFO who joins Dr. Martens from William
Grant & Sons Limited, one of the largest global spirits
companies, owners of premium brands including Glenfiddich Scotch
Whisky, The Balvenie Whisky and Hendrick's Gin. Prior to this,
Giles was at John Menzies plc as CFO (2016-20), and then
subsequently became CEO (2019-20). Giles qualified as a chartered
accountant with PwC and previously held a senior role at Commercial
Estates Group.
Paul Mason, Chair, said "Following a rigorous selection process,
we are delighted to appoint Giles as CFO. He is a very capable
finance leader with extensive experience in a number of sectors
and, most recently, his time in the branded spirits industry has
given him a good grounding in global brands and wholesale
distribution management. His knowledge of the public markets will
be a valuable asset to the team as Dr. Martens continues its growth
in the listed environment. I look forward to him joining the
Board."
Kenny Wilson, CEO, said "I am thrilled that Giles will be
joining the leadership team and the Board. He brings a range of
complementary skills and past experience that is highly relevant to
our brand-first strategy. I am looking forward to working with him
on the next phase of Dr. Martens' journey to become a GBP2billion
revenue footwear brand."
Giles Wilson said "Dr. Martens is an iconic brand I have long
admired, and I have been impressed by the passion and ambition
within the business. I am excited to be joining at such an
important stage in the Company's growth and I am looking forward to
working with Kenny and the team to drive the strategy forward."
Jon Mortimore, who is retiring from the Company as previously
announced, has agreed to stay with the business until the end of
the financial year.
There are no further disclosures required in respect of this
appointment pursuant to Listing Rule 9.6.13.
Enquiries
Investors and analysts
Bethany Barnes, Director of Investor Relations
Bethany.Barnes@drmartens.com +44 7825 187465
Beth Callum, Senior Investor Relations Analyst
Beth.Callum@drmartens.com +44 203 995 2644
Press
H/Advisors Maitland +44 207 379 5151
Clinton Manning +44 7711 972662
Gill Hammond, Director of Communications +44 7384 214248
Notes
Remuneration Arrangements
Giles Wilson's remuneration arrangements have been set in
accordance with the Directors' Remuneration Policy detailed in the
FY23 Annual Report. Further details will be set out in the
Directors' Remuneration Report for FY24.
About Dr. Martens
Dr. Martens is an iconic British brand founded in 1960 in
Northamptonshire. Produced originally for workers looking for
tough, durable boots, the brand was quickly adopted by diverse
youth subcultures and associated musical movements. Dr. Martens has
since transcended its working-class roots while still celebrating
its proud heritage and, six decades later, "Docs" or "DM's" are
worn by people around the world who use them as a symbol of
empowerment and their own individual attitude. The Company is a
constituent of the FTSE 250 index.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABJBRTMTBBBJJ
(END) Dow Jones Newswires
November 14, 2023 02:00 ET (07:00 GMT)
Dr. Martens (LSE:DOCS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Dr. Martens (LSE:DOCS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024